INTENSITY THERAPEUTICS, INC. (INTS) Stock Profile — Insider Trades & Financials

Net Income-$3.1M

EPS$-0.33

Market Cap$14.0M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Lewis Bender

CEO & Executive Director

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Founded: 2012
Employees: 7
Headquarters: Shelton, Connecticut, United States
Website

⚡

Core Efficiency

ROE?

-25.69%

ROA?

-21.64%

D/E Ratio?

0.19

📊

Profitability Ratios

Current Ratio?

5.92

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 11, 2026 (in 155 days)

Annual Report (10-K) — Based on filing pattern

Sep 11, 2026

Predicted10-K

Mar 27, 2026

10-KQ4 20251d after period end

Mar 27, 2026

10-KFY 202586d after period end

Nov 6, 2025

10-QQ3 20251d after period end

Aug 7, 2025

10-QQ2 20251d after period end

May 13, 2025

10-QQ1 20251d after period end

Mar 13, 2025

10-KQ4 20241d after period end

Mar 13, 2025

10-KFY 202572d after period end

Nov 13, 2024

10-QQ3 20247d after period end

Loading company sections...

INTENSITY THERAPEUTICS, INC.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness